To date, more than 14 complement inhibitors have been generated for core complement components (C3, C5) and complement regulators (FD, FI, etc.), and a total of nearly 40 clinical trials of these complement inhibitors have been completed or are under way in AMD. Here, CFI is linked to age-related macular degeneration.